The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

This scheme has consistently delivered the best returns in its Mid-Cap category across . This scheme has maintained a relatively low level of volatility within its Mid-Cap category over the past 3 ...

This scheme has consistently delivered the best returns in its Small-Cap category across . This scheme has maintained a relatively low level of volatility within its Small-Cap category over the past 3 ...